Glasgow-based life sciences firm Collagen Solutions officially launches sales process

Glasgow-based life sciences firm Collagen Solutions has confirmed that it is in talks with potential buyers of the company, having launched a formal sales process.
Jamal Rushdy, CEO of the Aim-quoted organisation. Picture: Sarah Pierce Photography.Jamal Rushdy, CEO of the Aim-quoted organisation. Picture: Sarah Pierce Photography.
Jamal Rushdy, CEO of the Aim-quoted organisation. Picture: Sarah Pierce Photography.

The Aim-quoted business said that after receiving interest in it, it has decided to conduct a formal review of the various strategic options available, to maximise value for shareholders.

“These options include, but are not limited to, the potential sale of the company or the sale of one or more of the company’s assets,” said the business.

Hide Ad
Hide Ad

It develops and manufactures collagen-based products and biomaterials used by the medical device industry, saying uses of its collagen products include cartilage repair and skin grafts.

The board has named England & Company and Goodbody Stockbrokers joint financial advisers, and Collagen Solutions is now considered to be in an “offer period”.

Read More
US group pumps £4.2m into Collagen Solutions

It comes as the business – which is led by chief executive Jamal Rushdy – prepares to provide a trading update with preliminary year-end revenue and cash balances next week.

Last month, it warned over widening full-year losses due to supply delays and the hesitancy of customers to commit to new orders as a result of the coronavirus outbreak.

“The company expects the loss for the year will be materially greater than anticipated due to increased costs from a development and manufacturing contract which has taken longer than originally anticipated,” it said at the time.

In December the group posted pre-tax losses of £1.2 million for the first half, and improving group revenues of £2.2m.

The business, which operates from Nova Business Park, was spun out from sausage skin maker Devro in 2008 in order to exploit biomedical applications for medical-grade collagen.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.With the coronavirus lockdown having a major impact on many of our advertisers - and consequently the revenue we receive - we are more reliant than ever on you taking out a digital subscription.Subscribe to scotsman.com and enjoy unlimited access to Scottish news and information online and on our app. With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit www.scotsman.com/subscriptions now to sign up.

Hide Ad
Hide Ad

Our journalism costs money and we rely on advertising, print and digital revenues to help to support them. By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Frank O'Donnell

Editorial Director

Related topics: